- Home
- QURE vs ASST Comparison
QURE vs ASST Comparison
Compare QURE & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | ASST |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.4M | 685.1M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | QURE | ASST |
|---|---|---|
| Price | $14.77 | $9.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $44.92 | $16.00 |
| AVG Volume (30 Days) | ★ 4.6M | 3.2M |
| Earning Date | 03-02-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.67 | ★ 82.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,107,000.00 | $633,489.00 |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $210.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 128.67 |
| 52 Week Low | $7.76 | $0.47 |
| 52 Week High | $71.50 | $13.40 |
Technical Indicators
Market Signals| Indicator | QURE | ASST |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 55.80 |
| Support Level | $13.35 | $0.74 |
| Resistance Level | $15.98 | $10.09 |
| Average True Range (ATR) | 1.43 | 0.72 |
| MACD | 0.28 | -0.17 |
| Stochastic Oscillator | 12.52 | 44.20 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About ASST Asset Entities Inc. Class B
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.